# China NMPA Drug Inspection - Anhui Bozhou Haomen Pharmaceutical Factory (Powdered Herbs/Granules) - Tetrapanax papyriferus

Source: https://www.globalkeysolutions.net/records/china_drug_inspection/anhui-bozhou-haomen-pharmaceutical-factory-powdered-herbsgranules/7238c4f6-cf1f-484f-9eb4-129252e693ba/
Source feed: China

> China NMPA drug inspection for Anhui Bozhou Haomen Pharmaceutical Factory (Powdered Herbs/Granules) published September 26, 2018. Drug: Tetrapanax papyriferus. On September 26, 2018, the Henan Provincial Food and Drug Administration announced the findings of drug inspections that

---

## Details

- Record Type: CHINA_DRUG_INSPECTION
- Title: Announcement from the Henan Provincial Food and Drug Administration regarding four batches of substandard drugs (No. 11, 2018)
- Company Name: Anhui Bozhou Haomen Pharmaceutical Factory (Powdered Herbs/Granules)
- Publication Date: 2018-09-26
- Drug Name: Tetrapanax papyriferus
- Inspection Finding: Properties do not meet regulations
- Action Taken: Relevant food and drug regulatory authorities have taken risk control measures such as sealing up, seizing, and suspending sales, and have investigated and dealt with the units that sourced the samples.
- Summary: On September 26, 2018, the Henan Provincial Food and Drug Administration announced the findings of drug inspections that identified four batches of substandard drugs from three manufacturers. Anhui Bozhou Haomen Pharmaceutical Pieces (Granules) Factory was cited for two products: Magnolia officinalis (batch 0161118R) had substandard content, and Tetrapanax papyriferus (batch 0170215R) showed a substandard appearance. Henan Baiyuankang Pharmaceutical Co., Ltd.'s Psoralea corylifolia (batch 160401) failed due to substandard content. Shangqiu Jinma Pharmaceutical Co., Ltd.'s Muxiang Shunqi Pills (batch 16041221) exhibited substandard content uniformity. These violations were determined against the standards of the Chinese Pharmacopoeia 2015 Edition, Part I. In response, the Henan Provincial Food and Drug Administration instructed local regulatory bodies to implement immediate risk control measures, including sealing, seizing, and suspending sales of the affected drugs. Additionally, thorough investigations and legal enforcement actions against the implicated companies were mandated.

Company: https://www.globalkeysolutions.net/companies/anhui-bozhou-haomen-pharmaceutical-factory-powdered-herbsgranules/82b59904-8131-4897-9f9c-e374d37a4660/